Alum Adjuvant Enhances Protection against Respiratory Syncytial Virus but Exacerbates Pulmonary Inflammation by Modulating Multiple Innate and Adaptive Immune Cells
Fig 3
Antibody-secreting plasma and germinal center B cell responses before challenge.
Bone marrow, splenocytes, and MLN (n = 5) were collected at 7 days post boost immunization (d.p.i.). MLN cells were stained with surface markers to germinal center (GC) B cells (GL7+B220+) by flow cytometry. (A) RSV-specific IgG (IgG, IgG1, IgG2a) antibody secreting cell responses in bone marrow after 1 day in vitro cultures. (B) RSV specific antibody secreting cell responses in MLN after 5 day in vitro cultures. (C) RSV specific antibody secreting cell responses in spleens after 5 day in vitro cultures. (D) Total B cells (CD19+IgD-) at 7 d.p.i.. (E) GC B cells (GL7+B220+) at 7 d.p.i.. Groups are the same as described in the Fig 1. Results are presented as mean ± SEM (n = 5). Statistical significances were performed by two- or one-way ANOVA and Tukey’s multiple comparison tests in GraphPad Prism; *** p<0.001, ** p<0.01, * p<0.05.